Literature DB >> 8334142

Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection.

T M Allen1, C B Hansen, L S Guo.   

Abstract

The development of long-circulating liposomes containing lipid derivatives of poly(ethylene glycol) (PEG), termed Stealth liposomes, has considerably improved the prospects for therapeutic applications of liposomal drug delivery systems. We have examined the pharmacokinetics and biodistribution of long-circulating, as compared to conventional, liposomes after subcutaneous (sc) administration in mice. Results obtained after subcutaneous administration were compared to those obtained after intravenous (iv) and intraperitoneal (ip) administration. Liposomes, following sc administration, appeared intact in the circulation subsequent to moving down the lymph node chains that drain the site of injection. Liposomes containing PEG-distearoylphosphatidylethanolamine (PEG-DSPE) resulted in the highest levels of small (80-90 nm) liposomes in the blood, with up to 30% of vivo label appearing in the blood at 12 to 24 h post-injection. In the absence PEG-DSPE approx. 4-fold lower levels of liposomes were found in the blood. Small size of the liposomes was critical to their ability to move into the circulation, with liposomes above 110-120 nm not appearing in blood to any significant extent. The presence of PEG-DSPE and cholesterol was important for the in vivo stability of the liposome after sc administration. Although liposome levels were significantly higher in the draining lymph nodes after sc administration, levels associated with other tissues were proportionately reduced relative to the iv and ip routes of administration. Liposomes appeared in blood after ip and sc administration with half-lives of approx. 0.6 and 9 h, respectively, and subsequent to appearing in blood had similar biodistribution, pharmacokinetics and half-lives (20.4 h) to liposomes given by the iv route.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8334142     DOI: 10.1016/0005-2736(93)90115-g

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  36 in total

1.  Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity.

Authors:  M R Niesman; K A Johnson; J S Penn
Journal:  Neurochem Res       Date:  1997-05       Impact factor: 3.996

Review 2.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

3.  Assessment of a liposomal formulation of ivermectin in rabbit after a single subcutaneous administration.

Authors:  Firas Bassissi; Anne Lespine; Michel Alvinerie
Journal:  Parasitol Res       Date:  2005-12-10       Impact factor: 2.289

4.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 5.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

6.  Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses.

Authors:  Shridhar Bale; Geraldine Goebrecht; Armando Stano; Richard Wilson; Takayuki Ota; Karen Tran; Jidnyasa Ingale; Michael B Zwick; Richard T Wyatt
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

7.  Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake.

Authors:  A E Hawley; L Illum; S S Davis
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

Review 8.  Transdermal drug delivery of insulin with ultradeformable carriers.

Authors:  Gregor Cevc
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis.

Authors:  Sean Allen; Yu-Gang Liu; Evan Scott
Journal:  Regen Eng Transl Med       Date:  2016-03-03

10.  Anthracycline extravasation injuries: management with dexrazoxane.

Authors:  Karin Jordan; Timo Behlendorf; Franziska Mueller; Hans-Joachim Schmoll
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.